|
1
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment - where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aung L, Tin AS, Quah TC and Pho RW:
Osteogenic sarcoma in children and young adults. Ann Acad Med
Singapore. 43:305–313. 2014.PubMed/NCBI
|
|
3
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dobrenkov K and Cheung NK: GD2-targeted
immunotherapy and radioimmunotherapy. Semin Oncol. 41:589–612.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lv YF, Dai H, Yan GN, Meng G, Zhang X and
Guo QN: Downregulation of tumor suppressing STF cDNA 3 promotes
epithelial-mesenchymal transition and tumor metastasis of
osteosarcoma by the Wnt/GSK-3β/β-catenin/Snail signaling pathway.
Cancer Lett. 373:164–173. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bacci G, Longhi A, Versari M, Mercuri M,
Briccoli A and Picci P: Prognostic factors for osteosarcoma of the
extremity treated with neoadjuvant chemotherapy: 15-Year experience
in 789 patients treated at a single institution. Cancer.
106:1154–1161. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Strauss SJ, Ng T, Mendoza-Naranjo A,
Whelan J and Sorensen PH: Understanding micrometastatic disease and
Anoikis resistance in Ewing family of tumors and
osteosarcoma. Oncologist. 15:627–635. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bielack S, Jürgens H, Jundt G, Kevric M,
Kühne T, Reichardt P, Zoubek A, Werner M, Winkelmann W and Kotz R:
Osteosarcoma: The COSS experience. Cancer Treat Res. 152:289–308.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moore DD and Luu HH: Osteosarcoma. Cancer
Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hatakeyama S: TRIM proteins and cancer.
Nat Rev Cancer. 11:792–804. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Borden KL: RING fingers and B-boxes:
Zinc-binding protein-protein interaction domains. Biochem Cell
Biol. 76:351–358. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reddy BA, Etkin LD and Freemont PS: A
novel zinc finger coiled-coil domain in a family of nuclear
proteins. Trends Biochem Sci. 17:344–345. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reymond A, Meroni G, Fantozzi A, Merla G,
Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, et
al: The tripartite motif family identifies cell compartments. EMBO
J. 20:2140–2151. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xing J, Weng L, Yuan B, Wang Z, Jia L, Jin
R, Lu H, Li XC, Liu YJ and Zhang Z: Identification of a role for
TRIM29 in the control of innate immunity in the respiratory tract.
Nat Immunol. 17:1373–1380. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang H, Palmbos PL, Wang L, Kim EH, Ney
GM, Liu C, Prasad J, Misek DE, Yu X, Ljungman M, et al: ATDC
(ataxia telangiectasia group D complementing) promotes
radioresistance through an interaction with the RNF8 ubiquitin
ligase. J Biol Chem. 290:27146–27157. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Napolitano LM and Meroni G: TRIM family:
Pleiotropy and diversification through homomultimer and
heteromultimer formation. IUBMB Life. 64:64–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hatakeyama S: Early evidence for the role
of TRIM29 in multiple cancer models. Expert Opin Ther Targets.
20:767–770. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song X, Fu C, Yang X, Sun D, Zhang X and
Zhang J: Tripartite motif-containing 29 as a novel biomarker in
non-small cell lung cancer. Oncol Lett. 10:2283–2288.
2015.PubMed/NCBI
|
|
20
|
Jiang N, Chen WJ, Zhang JW, Xu C, Zeng XC,
Zhang T, Li Y and Wang GY: Downregulation of miR-432 activates
Wnt/β-catenin signaling and promotes human hepatocellular carcinoma
proliferation. Oncotarget. 6:7866–7879. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun H, Dai X and Han B: TRIM29 as a novel
biomarker in pancreatic adenocarcinoma. Dis Markers.
2014:3178172014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qiu F, Xiong JP, Deng J and Xiang XJ:
TRIM29 functions as an oncogene in gastric cancer and is regulated
by miR-185. Int J Clin Exp Pathol. 8:5053–5061. 2015.PubMed/NCBI
|
|
23
|
Lai W, Zheng X, Huang Q, Wu X and Yang M:
Down-regulating ATDC inhibits the proliferation of esophageal
carcinoma cells. Eur Rev Med Pharmacol Sci. 18:3511–3516.
2014.PubMed/NCBI
|
|
24
|
Jiang T, Tang HM, Lu S, Yan DW, Yang YX
and Peng ZH: Up-regulation of tripartite motif-containing 29
promotes cancer cell proliferation and predicts poor survival in
colorectal cancer. Med Oncol. 30:7152013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tan ST, Liu SY and Wu B: TRIM29
Overexpression promotes proliferation and survival of bladder
cancer cells through NF-κB signaling. Cancer Res Treat.
48:1302–1312. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou XM, Sun R, Luo DH, Sun J, Zhang MY,
Wang MH, Yang Y, Wang HY and Mai SJ: Upregulated TRIM29 promotes
proliferation and metastasis of nasopharyngeal carcinoma via
PTEN/AKT/mTOR signal pathway. Oncotarget. 7:13634–13650. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Santin AD, Zhan F, Bellone S, Palmieri M,
Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, et al:
Gene expression profiles in primary ovarian serous papillary tumors
and normal ovarian epithelium: Identification of candidate
molecular markers for ovarian cancer diagnosis and therapy. Int J
Cancer. 112:14–25. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ai L, Kim WJ, Alpay M, Tang M, Pardo CE,
Hatakeyama S, May WS, Kladde MP, Heldermon CD, Siegel EM, et al:
TRIM29 suppresses TWIST1 and invasive breast cancer behavior.
Cancer Res. 74:4875–4887. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu J, Welm B, Boucher KM, Ebbert MT and
Bernard PS: TRIM29 functions as a tumor suppressor in
nontumorigenic breast cells and invasive ER+ breast
cancer. Am J Pathol. 180:839–847. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anderson ME: Update on Survival in
Osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhou W, Hao M, Du X, Chen K, Wang G and
Yang J: Advances in targeted therapy for osteosarcoma. Discov Med.
17:301–307. 2014.PubMed/NCBI
|
|
32
|
Guarino M, Rubino B and Ballabio G: The
role of epithelial-mesenchymal transition in cancer pathology.
Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tsai JH and Yang J: Epithelial-mesenchymal
plasticity in carcinoma metastasis. Genes Dev. 27:2192–2206. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hou CH, Lin FL, Hou SM and Liu JF: Cyr61
promotes epithelial-mesenchymal transition and tumor metastasis of
osteosarcoma by Raf-1/MEK/ERK/Elk-1/TWIST-1 signaling pathway. Mol
Cancer. 13:2362014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang L, Wu RL and Xu AM:
Epithelial-mesenchymal transition in gastric cancer. Am J Transl
Res. 7:2141–2158. 2015.PubMed/NCBI
|
|
36
|
Park SY, Korm S, Chung HJ, Choi SJ, Jang
JJ, Cho S, Lim YT, Kim H and Lee JY: RAP80 regulates
epithelial-mesenchymal transition related with metastasis and
malignancy of cancer. Cancer Sci. 107:267–273. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nantajit D, Lin D and Li JJ: The network
of epithelial-mesenchymal transition: Potential new targets for
tumor resistance. J Cancer Res Clin Oncol. 141:1697–1713. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Palma CS, Grassi ML, Thomé CH, Ferreira
GA, Albuquerque D, Pinto MT, Melo FU Ferreira, Kashima S, Covas DT,
Pitteri SJ, et al: Proteomic analysis of epithelial to mesenchymal
transition (EMT) reveals cross-talk between SNAIL and HDAC1
proteins in breast cancer cells. Mol Cell Proteomics. 15:906–917.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kosaka Y, Inoue H, Ohmachi T, Yokoe T,
Matsumoto T, Mimori K, Tanaka F, Watanabe M and Mori M: Tripartite
motif-containing 29 (TRIM29) is a novel marker for lymph node
metastasis in gastric cancer. Ann Surg Oncol. 14:2543–2549. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang L, Heidt DG, Lee CJ, Yang H, Logsdon
CD, Zhang L, Fearon ER, Ljungman M and Simeone DM: Oncogenic
function of ATDC in pancreatic cancer through Wnt pathway
activation and beta-catenin stabilization. Cancer Cell. 15:207–219.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yuan Z, Villagra A, Peng L, Coppola D,
Glozak M, Sotomayor EM, Chen J, Lane WS and Seto E: The ATDC
(TRIM29) protein binds p53 and antagonizes p53-mediated functions.
Mol Cell Biol. 30:3004–3015. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sho T, Tsukiyama T, Sato T, Kondo T, Cheng
J, Saku T, Asaka M and Hatakeyama S: TRIM29 negatively regulates
p53 via inhibition of Tip60. Biochim Biophys Acta. 1813:1245–1253.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Shibata MA, Yoshidome K, Shibata E, Jorcyk
CL and Green JE: Suppression of mammary carcinoma growth in vitro
and in vivo by inducible expression of the Cdk inhibitor p21.
Cancer Gene Ther. 8:23–35. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang L, Yang H, Abel EV, Ney GM, Palmbos
PL, Bednar F, Zhang Y, Leflein J, Waghray M, Owens S, et al: ATDC
induces an invasive switch in KRAS-induced pancreatic
tumorigenesis. Genes Dev. 29:171–183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xu R, Hu J, Zhang T, Jiang C and Wang HY:
TRIM29 overexpression is associated with poor prognosis and
promotes tumor progression by activating Wnt/β-catenin pathway in
cervical cancer. Oncotarget. 7:28579–28591. 2016. View Article : Google Scholar : PubMed/NCBI
|
